.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07E_IntestinalAntiinflammatoryAgents.A07EC02_Mesalazine.Mesalazine .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07E_IntestinalAntiinflammatoryAgents.A07EC02_Mesalazine.Mesalazine| name: | Mesalazine |
| ATC code: | A07EC02 | route: | oral |
| n-compartments | 1 |
Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an anti-inflammatory drug used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. It is approved and widely used today, primarily for induction and maintenance of remission in these conditions.
Pharmacokinetic parameters for healthy adults after single oral dose administration of mesalazine slow-release formulation.
Zhang, Y, et al., & Zuo, Z (2022). Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. Journal of controlled release : official journal of the Controlled Release Society 346 275–288. DOI:10.1016/j.jconrel.2022.04.024 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35461968
Lück, H, et al., & Sörgel, F (2009). Mesalazine pharmacokinetics and NAT2 phenotype. European journal of clinical pharmacology 65(1) 47–54. DOI:10.1007/s00228-008-0550-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18704388
Wiersma, H, et al., & Taminiau, J (2004). Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflammatory bowel diseases 10(5) 626–631. DOI:10.1097/00054725-200409000-00019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15472525